Tuesday, 2 March 2021 Reading time : 3 minutes

The Corona pandemic has put pharmaceutical companies worldwide into the spotlight. After and during the race for vaccines, the focus is now on their efficacy and speed of production.

Pfizer ahead on efficacy
A study from Israel conducted under real-life conditions confirms the high efficacy of the BioNTech / Pfizer vaccine. The result shows that the vaccine provides protection against disease symptoms in 94% of cases. ZKB Equity Research expects positive development for Pfizer shares ("overweight"). The vaccine from the British pharmaceutical company AstraZeneca is already approved in 50 countries and is used, among others, in the UK. Johnson & Johnson's vaccine is also considered to be highly effective; the U.S. Food and Drug Administration (FDA) confirms that the drug can prevent severe illness at a rate of over 85%.

Swiss pharmaceutical companies on the rise
Swiss pharmaceutical companies Novartis, Roche and Lonza remain well positioned in the market. Novartis is increasing its presence in emerging markets, particularly in China, the world's second-largest healthcare market after the US. Roche has benefited from high demand for Covid 19 tests and has a stable business model, while Lonza has a strong development pipeline and a high level of innovation to generate steadily increasing earnings. All three stocks are rated "overweight" by ZKB Equity Research.
 

Barrier Reverse Convertible on AstraZeneca, Johnson & Johnson and Pfizer 

• Guaranteed Coupon of 8.00%* p.a.
• Barriere of 70.00%* 
• 12 months duration 
• Subscription period ends on 03.03.2021 
• Termsheet

Barrier Reverse Convertible on Novartis, Roche and Lonza 

• Guaranteed Coupon of 10.00%* p.a. 
• Barrier of 70.00%* 
• 15 months Duration 
• Subscription period ends on 09.03.2021 
• Termsheet

*indicative

 

Disclaimer
This communication is for marketing purposes. It is neither an offer nor an invitation to submit an offer, to purchase or to subscribe to securities and does not constitute investment advice. You should consult your advisors before making an investment decision.
Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, financial condition, development or performance of the issuer to be materially different from any future results, financial condition, development or performance expressed or implied by such statements.
The present document has not been drawn up by the research department as defined in the rules of the “Directives on the Independence of Financial Research” published by the Swiss Bankers Association, hence these rules do not apply to this document.
If securities are mentioned in the communication, the base prospectus, the final terms and any key information document may be obtained free of charge from Zürcher Kantonalbank, Bahnhofstrasse 9, 8001 Zurich, VRIS, and from www.zkb.ch/finanzinformationen.